Related Experiment Videos
Driving ability under long-term treatment with transdermal fentanyl
Rainer Sabatowski1, Susanne Schwalen, Klaus Rettig
1Department of Anesthesiology, University of Cologne, Cologne, Germany.
Journal of Pain and Symptom Management
|February 5, 2003
Summary
Long-term transdermal fentanyl for chronic pain does not impair driving ability. Stable doses of this opioid therapy showed no significant cognitive or psychomotor performance deficits in patients compared to controls.
Area of Science:
- Neuroscience
- Pharmacology
- Pain Management
Background:
- Opioid therapy can cause neuropsychological side effects, typically diminishing within weeks.
- Long-term effects of transdermal fentanyl on complex activities like driving remain unclear.
Purpose of the Study:
- To evaluate the impact of stable-dose transdermal fentanyl on psychomotor and cognitive performance in patients with chronic non-cancer pain.
- To assess fitness to drive in patients undergoing long-term transdermal fentanyl therapy.
Main Methods:
- Prospective trial involving patients on stable transdermal fentanyl doses for ≥2 weeks.
- Computerized tests measuring attention, reaction time, visual orientation, motor coordination, and vigilance.
- Comparison of patient performance against matched healthy volunteers.
Main Results:
- No significant performance differences were observed between fentanyl patients and control groups in any tested cognitive or psychomotor measures.
- The study included 21 patients in the per-protocol analysis after excluding 9 for protocol violations.
- Fitness to drive thresholds, as per German law, did not significantly differ between groups.
Conclusions:
- Stable doses of transdermal fentanyl for chronic non-cancer pain are not linked to significant psychomotor or cognitive impairments.
- Transdermal fentanyl therapy at stable doses does not appear to compromise fitness to drive.